akt3 (Carna Inc)
Structured Review
Akt3, supplied by Carna Inc, used in various techniques. Bioz Stars score: 96/100, based on 2 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/01-103/AKT3/10__1158_slash_0008___5472__can___17___0484-85-67-69
Average 96 stars, based on 2 article reviews
Images
Related Articles
other:Article Title: PI-273, a Substrate-Competitive, Specific Small-Molecule Inhibitor of PI4KIIα, Inhibits the Growth of Breast Cancer Cells Article Snippet: 1 PI-273, a substrate-competitive, specific small molecule inhibitor of PI4KIIα, inhibits the growth of breast cancer cells Running title: The First PI4KIIα Substrate-Competitive Specific Inhibitor Jiangmei Li1, 7 #, Zhen Gao1, 6 #, Dan Zhao2, 6#, Lunfeng Zhang1,6, Xinhua Qiao1, 6, Yingying Zhao1, 7, Hong Ding2, Panpan Zhang 5 ,6,7, Junyan Lu2, Jia Liu7, Hualiang Jiang2, Cheng Luo2 ,4*, Chang Chen1, 3, 6* 1National Laboratory of Biomacromolecules, CAS Center for Excellence in Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences, 15 Datun Road, Chaoyang District, Beijing, 100101, China 2Drug Discovery and Design Center, State Key Laboratory of Drug Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China 3Beijing Institute for Brain Disorders, No. 10 Xitoutiao, You An Men, Beijing, 100069, China 4The State Key Laboratory of Toxicology and Medical Countermeasures, Academy of Military Medical Science, Beijing, China 5 Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China 6University of Chinese Academy of Sciences, 19 Yuquan Road, Shijingshan District, Beijing, 100049, China 7Shanghai Institute for Advanced Immunochemical Studies, ShanghaiTech University, Shanghai, China # These authors contributed equally to this work.. Running title: The First PI4KIIα Substrate-competitive Specific Inhibitor Key words: Phosphatidylinositol 4-kinase IIα; Substrate-competitive small-molecule inhibitor; Virtual screening; Breast cancer Grant Support: This research was supported by National Key R&D Program of China (2017YFA0504000, 2016YFC0903100 to C. Chen), Personalized Medicines-Molecular Signature-based Drug Discovery and Development, the Strategic Priority Research Program of Research. on August 22, 2017.. © 2017 American Association for Cancercancerres.aacrjournals.org Downloaded from Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. |
